Is Circulating Tumor DNA Ready for Clinical Use in Large B-cell Lymphoma?

Response assessment after frontline therapy for large B-cell lymphoma risk-stratifies patients into those at low risk for relapse and those with residual disease. Positron emission tomography scans form the cornerstone of the response criteria but cannot detect molecular-only disease. Circulating tumor DNA detects measurable residual disease (MRD) after therapy which is emerging as an adjunct tool for complex clinical decision-making. We discuss how MRD after therapy can be clinically implemented and additional data needed to unlock its full potential.